| ☒   ☐ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the years ended December 31, 2018 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________  |
|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Nevada                                                         |   | 32-0379665                           |
|----------------------------------------------------------------|--------|--------------------------------------|
| (State or other jurisdiction of incorporation or organization) |   | (I.R.S. Employer Identification No.) |
|                                                           |   |                                 |
| 57 West 57th Street, Suite 400New York, New York               |   | 10019                                |
| (Address of principal executive offices)                       |   | (Zip Code)                           |

**(646) 416-7896**

| Title of each class |   | Trading Symbol(s) |   | Name of each exchange on which registered |
|---------------------|--------|-------------------|--------|-------------------------------------------|
|                |   |              |   |                                      |
| None                |   |                   |   |                                           |

| Large accelerated filer ☐           | Accelerated filer ☐         |
|-------------------------------------------|-----------------------------------|
| Non-accelerated filer   ☒ | Smaller reporting company ☒ |
|                                           | Emerging growth company ☐   |

----

| Exhibit   |   |                                                                                                                                                                                         |
|-----------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Number    |   | Description                                                                                                                                                                                  |
|      |   |                                                                                                                                                                                         |
| 2.1 (1)   |   | Share Exchange Agreement, dated June 30, 2014, by and between Cell Source, Ltd., and Ticket to See, Inc.                                                                                     |
| 3.1 (1)   |   | Articles of Association of Cell Source Limited, dated August 14, 2011, as amended on November 11, 2013                                                                                       |
| 3.2 (2)   |   | Articles of Incorporation of Ticket to See, Inc., dated June 6, 2012                                                                                                                         |
| 3.3 (3)   |   | Certificate of Amendment to Articles of Incorporation of Ticket to See, Inc., dated June 23, 2014                                                                                            |
| 3.3 (4)   |   | Certificate of Amendment to Articles of Incorporation of Ticket to See, Inc., dated May 20, 2014                                                                                             |
| 3.4 (2)   |   | Bylaws of Cell Source, Inc., dated June 6, 2012                                                                                                                                              |
| 3.5 (18)  |   | Certificate of Designation with respect to Series A Preferred Stock dated November 14, 2016                                                                                                  |
| 10.1 (1)  |   | Form of Subscription Agreement                                                                                                                                                               |
| 10.2 (1)  |   | Form of Registration Rights Agreement                                                                                                                                                        |
| 10.3 (1)  |   | Form of Investor Warrant                                                                                                                                                                     |
| 10.4 (1)  |   | Form of Consultant Warrant(8)                                                                                                                                                                |
| 10.5 (1)  |   | Form of Researcher Company Warrant                                                                                                                                                           |
| 10.6 (1)  |   | Form of Company Warrant                                                                                                                                                                      |
| 10.7 (1)  |   | Form of Lockup Agreement (included in Exhibit 2.1)                                                                                                                                           |
| 10.8 (1)  |   | Research and License Agreement by and between Yeda Research and Development Company Limited and Cell Source                Limited, dated October 3, 2011                                    |
| 10.9 (1)  |   | Amendment to Research and License Agreement                                                                                                                                                  |
| 10.10 (1) |   | Evaluation and Exclusive Option Agreement by and between Yeda Research and Development Company Limited and Cell                Source Limited, dated Oct. 3, 2011 (included in Exhibit 10.7) |
| 10.11 (1) |   | Amendment dated April 1, 2014 to Evaluation and Exclusive Option Agreement by and between Yeda Research and                Development Company Limited and Cell Source Limited               |
| 10.12 (1) |   | Second Amendment dated June 22, 2014 to Evaluation and Exclusive Option Agreement by and between Yeda Research and                Development Company Limited and Cell Source Limited        |
| 10.13 (1) |   | Consulting Agreement by and between Cell Source Limited and Professor Yair Reisner                                                                                                           |
| 10.14 (6) |   | Form of Amendment No. 1 to Registration Rights Agreement                                                                                                                                     |
| 10.15 (7) |   | Bridge Funding Agreement                                                                                                                                                                     |
| 10.16 (5) |   | Third Amendment dated June 22, 2014 to Evaluation and Exclusive Option Agreement by and between Yeda Research and                Development Company Limited and Cell Source Limited         |
| 10.17 (8) |   | Form of Consulting Agreement pursuant to which the Company issued warrants to purchase an aggregate of 2,000,000                shares of the Company’s common stock                   |
| 10.18 (9) |   | Form of Promissory Note issued to the Company’s Chief Executive Officer                                                                                                                |
| 10.19(10) |   | Form of March 2015 Promissory Note                                                                                                                                                           |
| 10.20(10) |   | Form of March 2015 Warrant                                                                                                                                                                   |

----

| 10.21(11) |   | Form of Note Amendment Letter Agreement                                                                                                                                                                          |
|-----------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.22(11) |   | Form of May 2015 Note                                                                                                                                                                                            |
| 10.23(11) |   | Form of May 2015 Warrant                                                                                                                                                                                         |
| 10.24(12) |   | Form of Advisory/Consulting Agreement                                                                                                                                                                            |
| 10.25(13) |   | Zolty Promissory Note                                                                                                                                                                                            |
| 10.26(13) |   | Zolty Warrant                                                                                                                                                                                                    |
| 10.27(13) |   | Form of July 2015 Convertible Promissory Note                                                                                                                                                                    |
| 10.28(13) |   | Form of July 2015 Warrant                                                                                                                                                                                        |
| 10.29(15) |   | Form of Bridge Note Subscription Agreement                                                                                                                                                                       |
| 10.30(15) |   | Form of Convertible Note                                                                                                                                                                                         |
| 10.31(15) |   | Form of March 2016 Note                                                                                                                                                                                          |
| 10.32(15) |   | Form of March 2016 Warrant                                                                                                                                                                                       |
| 10.33(18) |   | Form of July 2016 Warrants                                                                                                                                                                                       |
| 10.34(18) |   | Second Amendment to Research and License Agreement dated as of November 28, 2016 between the Company and Yeda                Research and Development Company Limited                                            |
| 10.35(18) |   | Third Amendment to Research and License Agreement dated as of March 29, 2018 between the Company and Yeda Research                and Development Company Limited                                                |
| 10.36(18) |   | Fourth Amendment to Research and License Agreement dated as of March 30, 2018 between the Company and Yeda Research                and Development Company Limited                                               |
| 10.37(16) |   | Convertible Note due July 27, 2016                                                                                                                                                                               |
| 10.38(17) |   | Promissory Note dated May 10, 2016                                                                                                                                                                               |
| 10.39(19) |   | Sponsored Research Agreement dated November 28, 2018 between The University of Texas M.D. Anderson Cancer Center                and Cell Source Limited                                                          |
| 10.40(19) |   | Agreement for Veto Cell Production and Clinical Trial Program dated February 19, 2019 between The University of                Texas M.D. Anderson Cancer Center and Cell Source Limited                         |
| 16.1(1)   |   | Letter from Paritz & Company, P.A.                                                                                                                                                                           |
| 21(14)    |   | Subsidiaries                                                                                                                                                                                                     |
| 31.1      |   | Certification of principal executive and principal financial officer pursuant to Section 302 of the                Sarbanes-Oxley Act of 2002                                                          |
| 32.1      |   | Certification of principal executive and principal financial officer pursuant to Section 906 of the Sarbanes-Oxley                Act                  of 2002 |
| 101.INS * |   | XBRL Instance Document                                                                                                                                                                                           |
| 101.SCH * |   | XBRL Taxonomy Extension Schema Document                                                                                                                                                                          |
| 101.CAL * |   | XBRL Taxonomy Extension Calculation Linkbase Document                                                                                                                                                            |
| 101.DEF * |   | XBRL Taxonomy Extension Definition Linkbase Document                                                                                                                                                             |
| 101.LAB * |   | XBRL Taxonomy Extension Label Linkbase Document                                                                                                                                                                  |
| 101.PRE * |   | XBRL Taxonomy Extension Presentation Linkbase Document                                                                                                                                                           |
| (1)  | Incorporated by reference to the Company’s Current Report on Form 8-K filed with the Securities and Exchange                Commission on July 1, 2014.              |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2)  | Incorporated by reference to the Company’s Registration Statement on Form S-1 filed with the Securities and                Exchange Commission on June 6, 2012.      |
| (3)  | Incorporated by reference to the Company’s Form 8-K filed with the Securities and Exchange Commission on June 26,                2014.                               |
| (4)  | Incorporated by reference to the Company’s Form 8-K filed with the Securities and Exchange Commission on June 6,                2014.                                |
| (5)  | Incorporated by reference to the Company’s Form 10-Q filed with the Securities and Exchange Commission on August                19, 2014.                            |
| (6)  | Incorporated by reference to the Company’s Registration Statement on Form S-1 filed with the Securities and                Exchange Commission on August 8, 2014.    |
| (7)  | Incorporated by reference to the Company’s Registration Statement Form S-1/A filed with the Securities and Exchange                Commission on September 23, 2014. |
| (8)  | Incorporated by reference to the Company’s Form 8-K filed with the Securities and Exchange Commission on June 30,                2014.                               |
| (9)  | Incorporated by reference to the Company’s Form 8-K filed with the Securities and Exchange Commission on December                2, 2014.                            |
| (10) | Incorporated by reference to the Company’s Form 8-K filed with the Securities and Exchange Commission on April 1,                2015.                               |
| (11) | Incorporated by reference to the Company’s Form 8-K filed with the Securities and Exchange Commission on June 3,                2015.                                |
| (12) | Incorporated by reference to the Company’s Form 8-K filed with the Securities and Exchange Commission on June 10,                2015.                               |
| (13) | Incorporated by reference to the Company’s Form 8-K filed with the Securities and Exchange Commission on July 28,                2015.                               |
| (14) | Incorporated by reference to the Company’s Form 10-K filed with the Securities and Exchange Commission on March 13,                2015.                             |
| (15) | Incorporated by reference to the Company’s Form 10-K filed with the Securities and Exchange Commission on April 14,                2016.                             |
| (16) | Incorporated by reference to the Company’s Form 10-Q filed with the Securities and Exchange Commission on May 13,                2016.                               |
| (17) | Incorporated by reference to the Company’s Form 10-Q filed with the Securities and Exchange Commission on August                15, 2016.                            |
| (18) | Incorporated by reference to the Company’s Form 10-K filed with the Securities and Exchange Commission on July 25,                2018.                              |
| (19) | Certain information has been excluded from this exhibit because (i) it is not material and (ii) would be                competitively harmful if publicly disclosed.       |
| *    | Filed with Form 10-K filed with the Securities and Exchange Commission on April 1, 2019                                                                                    |

----

|                       | CELL SOURCE, INC. |
|----------------------------|-------------------|
|                       |              |   |   |
|                       |              |   |   |
| Dated:  June 19, 2019 | By:               | /s/ Itamar Shimrat |
|                       |              | Name:  | Itamar Shimrat |
|                       |              | Title: | Chief Executive Officer and |
|                       |              |   | Chief Financial Officer |
|                       |              |   | (Principal Executive, Financial and Accounting Officer) |

| SIGNATURE |                    | TITLE  |                                                          | DATE   |
|-----------|-------------------------|--------|---------------------------------------------------------------|--------|
|      |                    |   |                                                          |   |   |
|      |                    |   |                                                          |   |   |
| By:  | /s/ Dennis Brown   |   | Chairman                                                      |   | June 19,                      2019 |
|      | Dennis Brown            |   |                                                          |   |   |
|      |                    |   |                                                          |   |   |
|      |                    |   |                                                          |   |   |
| By:       | /s/ Itamar Shimrat |   | Chief Executive Officer, Chief Financial Officer and Director |   | June 19,                      2019 |
|      | Itamar Shimrat          |   | (Principal Executive, Financial and Accounting Officer)       |   |   |
|      |                    |   |                                                          |   |   |
|      |                    |   |                                                          |   |   |
| By:       | /s/ Ben Friedman   |   | Director                                                      |   | June 19,                      2019 |
|      | Ben Friedman            |   |                                                          |   |   |
|      |                    |   |                                                          |   |   |
|      |                    |   |                                                          |   |   |
| By:       | /s/ David Zolty    |   | Director                                                      |   | June 19,                      2019 |
|      | David Zolty             |   |                                                          |   |   |